New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
06:10 EDTACHNAchillion begins dosing with ACH-3422 in its ongoing Phase 1 clinical trial
Achillion Pharmaceuticals announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection, or HCV, in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced that the FDA has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 12, 2014
06:00 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Stocks with implied volatility top IV index mean; DISH (DISH) 31, Achillion (ACHN) 128 according to iVolatility.
September 10, 2014
05:58 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Subscribe for More Information
September 9, 2014
06:03 EDTACHNStocks with implied volatility above IV index mean; DISH ACHN
Subscribe for More Information
September 5, 2014
14:44 EDTACHNAchillion November volatility elevated into expected release of viral data
Subscribe for More Information
05:59 EDTACHNStocks with implied volatility above IV index mean; ACHN MCD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use